AB-FUBINACA is a synthetic cannabinoid compound. Members of this group produce cannabis-like effects when administered.
AB-FUBINACA was originally developed by Pfizer in 2009 as an analgesic medication,but was not pursued for human use. Subsequently in 2012, it was discovered as an ingredient in synthetic cannabis blends in Japan along with a related compound AB-PINACA which had not previously been reported.
Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. AB-FUBINACA is orally active when dissolved in a lipid, which can increase the duration significantly. Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
Unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects and higher toxicity. It is strongly discouraged to take this substance for extended periods of time or in high doses.
Sedation – Generally, the effects on the user’s energy levels are primarily sedating.
Spontaneous physical sensations
Motor control loss
Changes in felt gravity
Perception of bodily heaviness or Perception of bodily lightness
Paranoia – All cannabinoids are capable of inducing paranoia at high doses or with chronic administration.
AB-FUBINACA is sold for research purposes only and is not be utilized for any other purposes.